vs

Side-by-side financial comparison of NICOLET BANKSHARES INC (NIC) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

NICOLET BANKSHARES INC is the larger business by last-quarter revenue ($104.0M vs $83.1M, roughly 1.3× PROCEPT BioRobotics Corp). NICOLET BANKSHARES INC runs the higher net margin — 38.8% vs -38.1%, a 76.8% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 12.5%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 12.5%).

Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

NIC vs PRCT — Head-to-Head

Bigger by revenue
NIC
NIC
1.3× larger
NIC
$104.0M
$83.1M
PRCT
Growing faster (revenue YoY)
PRCT
PRCT
+7.7% gap
PRCT
20.2%
12.5%
NIC
Higher net margin
NIC
NIC
76.8% more per $
NIC
38.8%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
12.5%
NIC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NIC
NIC
PRCT
PRCT
Revenue
$104.0M
$83.1M
Net Profit
$40.3M
$-31.6M
Gross Margin
64.9%
Operating Margin
48.3%
-4.1%
Net Margin
38.8%
-38.1%
Revenue YoY
12.5%
20.2%
Net Profit YoY
16.9%
-27.9%
EPS (diluted)
$2.63
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NIC
NIC
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$104.0M
$76.4M
Q3 25
$102.9M
$83.3M
Q2 25
$95.7M
$79.2M
Q1 25
$89.4M
$69.2M
Q4 24
$92.4M
$68.2M
Q3 24
$90.7M
$58.4M
Q2 24
$85.0M
$53.4M
Net Profit
NIC
NIC
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$40.3M
$-29.8M
Q3 25
$41.7M
$-21.4M
Q2 25
$36.0M
$-19.6M
Q1 25
$32.6M
$-24.7M
Q4 24
$34.5M
$-18.9M
Q3 24
$32.5M
$-21.0M
Q2 24
$29.3M
$-25.6M
Gross Margin
NIC
NIC
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
NIC
NIC
PRCT
PRCT
Q1 26
-4.1%
Q4 25
48.3%
-40.6%
Q3 25
50.4%
-27.8%
Q2 25
46.8%
-28.0%
Q1 25
44.9%
-39.7%
Q4 24
46.8%
-28.9%
Q3 24
45.0%
-38.4%
Q2 24
43.3%
-50.3%
Net Margin
NIC
NIC
PRCT
PRCT
Q1 26
-38.1%
Q4 25
38.8%
-39.1%
Q3 25
40.6%
-25.7%
Q2 25
37.6%
-24.7%
Q1 25
36.4%
-35.8%
Q4 24
37.3%
-27.6%
Q3 24
35.8%
-35.9%
Q2 24
34.5%
-48.0%
EPS (diluted)
NIC
NIC
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$2.63
$-0.54
Q3 25
$2.73
$-0.38
Q2 25
$2.34
$-0.35
Q1 25
$2.08
$-0.45
Q4 24
$2.21
$-0.34
Q3 24
$2.10
$-0.40
Q2 24
$1.92
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NIC
NIC
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$245.6M
Total DebtLower is stronger
$134.9M
$51.7M
Stockholders' EquityBook value
$1.3B
$347.7M
Total Assets
$9.2B
$487.1M
Debt / EquityLower = less leverage
0.11×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NIC
NIC
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
NIC
NIC
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$134.9M
$51.6M
Q3 25
$134.6M
$51.6M
Q2 25
$134.3M
$51.5M
Q1 25
$156.6M
$51.5M
Q4 24
$161.4M
$51.5M
Q3 24
$161.2M
$51.4M
Q2 24
$162.4M
$51.4M
Stockholders' Equity
NIC
NIC
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$1.3B
$365.9M
Q3 25
$1.2B
$380.3M
Q2 25
$1.2B
$385.8M
Q1 25
$1.2B
$389.2M
Q4 24
$1.2B
$402.2M
Q3 24
$1.1B
$241.2M
Q2 24
$1.1B
$251.8M
Total Assets
NIC
NIC
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$9.2B
$508.1M
Q3 25
$9.0B
$511.5M
Q2 25
$8.9B
$513.1M
Q1 25
$9.0B
$519.4M
Q4 24
$8.8B
$534.0M
Q3 24
$8.6B
$374.1M
Q2 24
$8.6B
$374.4M
Debt / Equity
NIC
NIC
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.11×
0.14×
Q3 25
0.11×
0.14×
Q2 25
0.11×
0.13×
Q1 25
0.13×
0.13×
Q4 24
0.14×
0.13×
Q3 24
0.14×
0.21×
Q2 24
0.15×
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NIC
NIC
PRCT
PRCT
Operating Cash FlowLast quarter
$153.5M
Free Cash FlowOCF − Capex
$149.4M
FCF MarginFCF / Revenue
143.7%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
3.81×
TTM Free Cash FlowTrailing 4 quarters
$275.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NIC
NIC
PRCT
PRCT
Q1 26
Q4 25
$153.5M
$-10.3M
Q3 25
$45.9M
$-6.6M
Q2 25
$38.9M
$-15.0M
Q1 25
$41.8M
$-17.0M
Q4 24
$133.7M
$-32.4M
Q3 24
$39.6M
$-18.8M
Q2 24
$37.3M
$-15.7M
Free Cash Flow
NIC
NIC
PRCT
PRCT
Q1 26
Q4 25
$149.4M
$-12.2M
Q3 25
$45.9M
$-9.5M
Q2 25
$38.4M
$-17.8M
Q1 25
$41.3M
$-18.8M
Q4 24
$116.8M
$-33.6M
Q3 24
$34.7M
$-19.0M
Q2 24
$34.4M
$-16.8M
FCF Margin
NIC
NIC
PRCT
PRCT
Q1 26
Q4 25
143.7%
-15.9%
Q3 25
44.6%
-11.4%
Q2 25
40.1%
-22.5%
Q1 25
46.2%
-27.2%
Q4 24
126.4%
-49.2%
Q3 24
38.3%
-32.6%
Q2 24
40.5%
-31.4%
Capex Intensity
NIC
NIC
PRCT
PRCT
Q1 26
Q4 25
3.9%
2.4%
Q3 25
0.0%
3.4%
Q2 25
0.6%
3.5%
Q1 25
0.5%
2.7%
Q4 24
18.3%
1.7%
Q3 24
5.4%
0.4%
Q2 24
3.5%
2.0%
Cash Conversion
NIC
NIC
PRCT
PRCT
Q1 26
Q4 25
3.81×
Q3 25
1.10×
Q2 25
1.08×
Q1 25
1.28×
Q4 24
3.88×
Q3 24
1.22×
Q2 24
1.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NIC
NIC

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons